Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Just a day after the S&P 500 and Nasdaq climbed into record territory, U.S. stocks end mixed, with American Express (AXP) and 3M (MMM) dragging the Dow, and more tariff drama muting markets.

When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

A local nonprofit is navigating uncertainty with several programs on the chopping block. Disability Rights Ohio serves as an advocate for people with disabilities. They help with jobs, education, ...

Sarepta Therapeutics announced late Friday evening that it will not comply with the Food and Drug Administration's ...

Drugmaker Sarepta Therapeutics said it won’t comply with a request from the FDA to halt all shipments of its gene therapy ...